Hims & Hers misses revenue estimates as strategy shift hits sales
Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company’s shift toward branded GLP-1 weight-loss drugs pressured its margins and domestic sales. Shares of the Hims & Hers company fell more than 12% in extended trading to $25.55, even as Hims raised its…